GlassScriptPhysician profile
Sharon Cave-Adens
NPI 1093089567
$3,864.08
in general payments reported to CMS, 2019-2025
23 companies · $486 in 2025
The $486 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,690 · 2022: $367 · 2023: $734 · 2024: $588 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,807.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $657.71 | 2021 | |
| Novo Nordisk INC | $608.67 | 2021-2023 | |
| Braeburn INC. | $448.02 | 2024-2025 | Brixadi |
| Abbvie INC. | $375.91 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $303.95 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $250.00 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $197.18 | 2021 | |
| Idorsia Pharmaceuticals US INC | $143.66 | 2023 | Quviviq |
| Regeneron Healthcare Solutions, INC. | $121.69 | 2024 | Dupixent |
| Amgen INC. | $108.56 | 2024 | Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $108.33 | 2022 | |
| Abbott Laboratories | $108.10 | 2023 | Cardiomems |
| Takeda Pharmaceuticals U.S.A., INC. | $74.94 | 2023 | Trintellix |
| Lilly USA, LLC | $66.33 | 2021-2022 | |
| Viiv Healthcare Company | $55.44 | 2025 | Apretude |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipher Pharmaceuticals US LLC | $55.29 | 2025 | Spinosad, Natroba |
| Indivior INC. | $47.51 | 2025 | Sublocade |
| Axsome Therapeutics, INC. | $42.02 | 2023 | Auvelity |
| Novartis Pharmaceuticals Corporation | $30.02 | 2021-2022 | |
| Lundbeck LLC | $18.49 | 2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $14.93 | 2023 | Austedo Xr |
| Alkermes, INC. | $14.48 | 2023 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $12.85 | 2023 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Cave-Adens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.